BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
⚡ Executive Takeaway
J&J's teclistamab combo secures a record-breaking 55-day FDA approval under the Commissioner's National Priority Voucher pilot, setting a new benchmark for accelerated hematology reviews. Meanwhile, the strategic "onshoring" thesis gains momentum as Atavistik Bio closes a $40M Series B extension (bringing total proceeds to $160M) for allosteric blood disorder therapies. CVS Health and Google Cloud unveil Health100, an AI-native consumer engagement platform, while the administration's TrumpRx portal faces early headwinds one month post-launch with daily searches dropping to approximately 11,000 and only 44 drugs available. 👉 Read Full Analysis
🔮 What To Watch
The "Priority Review" Cascade: With Tec-Dara now approved in just 55 days, the FDA Commissioner's National Priority Voucher (CNPV) pilot has delivered three historic approvals since February. Watch whether mid-cap oncology players pursue aggressive U.S. manufacturing strategies to qualify for this pathway.
ACIP's "Kennedy" Shift: Following last week's appointment of Drs. Sean Downing and Angelina Farella to the ACIP, watch for schedule reassessments at the upcoming March 18-19 meeting. The focus is expected to shift toward "individualized" pediatric guidelines.
Mavenclad's U.S. Cliff: Merck KGaA expects a significant impact from generic entries in 2026. This creates an immediate opening for TG Therapeutics (Briumvi) and Roche (Ocrevus) to capture displaced relapsing MS market share.
🚀 Today's Top Story
FDA Approves J&J's Tec-Dara Combo in Record 55 Days
What Happened: The FDA granted approval to Johnson & Johnson's Tec-Dara (teclistamab plus daratumumab hyaluronidase-fihj) for relapsed/refractory multiple myeloma in adults who have received at least one prior line of therapy.
Why It Matters: This marks the third approval under the CNPV pilot program. In the Phase 3 MajesTEC-3 trial, the combo reduced the risk of disease progression or death by 83% (HR 0.17; p<.0001) compared to standard physician-choice regimens. The 36-month PFS rate was 83.4% versus 29.7% for standard of care.
Executive Impact: J&J has successfully converted teclistamab monotherapy from accelerated to traditional approval while simultaneously securing a high-potency combo indication. This "synergy-first" strategy effectively positions competitors in a multi-year lag for second-line standard-of-care status. The approval also represents the earliest indication for a bispecific antibody in multiple myeloma.
🎗️ Oncology & Rare Disease
Atavistik Bio ($160M Series B)
The Raise: The Cambridge-based startup closed a $40M Series B extension from RA Capital Management, bringing total round proceeds to $160M.
The Science: The capital targets "allosteric" medicines for hereditary hemorrhagic telangiectasia (HHT) and myeloproliferative neoplasms. Using its Atavis platform, the company finds small-molecule "dimmer switches" for disease-driving enzymes like AKT1 rather than traditional active-site inhibitors. Clinical trials in HHT are expected in 1H 2026.
Oncolytics Biotech (REO 033)
Trial Launch: Launched its Phase 2 randomized trial evaluating pelareorep in second-line RAS-mutated metastatic colorectal cancer. The study will randomize 60 patients to pelareorep plus bevacizumab/FOLFIRI versus standard of care, with preliminary data expected by year-end.
Galderma (Nemluvio Outlook)
Guidance Upgrade: Doubled its peak sales guidance for Nemluvio (nemolizumab) from >$2B to >$4B globally, citing a stronger-than-anticipated first year in the U.S. and EU in prurigo nodularis and atopic dermatitis. The company reported $452M in 2025 sales.
🔬 Clinical & Research Updates
Vertex Pharmaceuticals (JOURNAVX)
Data: Presented Phase 4 data showing that 90.9% of patients remained opioid-free through 14 days post-surgery when using suzetrigine as part of a multimodal treatment following plastic surgery. 90.7% rated pain control as excellent, very good, or good.
Gilead (Yeztugo Campaign)
Commercialization: Continues its "One2PrEP" consumer campaign for its twice-yearly HIV PrEP medication, featuring a reimagined version of Ciara's "1, 2 Step." The campaign aims to capitalize on the shift from daily orals to long-acting injectables, supporting Gilead's projection of $800M in 2026 sales.
🏢 Corporate Developments
CVS Health & Google Cloud
Partnership: Announced a strategic partnership to build Health100, an AI-native consumer engagement platform. The platform will use Google Cloud's Gemini models and BigQuery to provide real-time, omni-channel support, with future biometric wearable integration planned.
Minnesota Medical Technologies ($20.6M)
Funding: Secured Series A funding to support the commercial launch of StaySure, an FDA-cleared minimally invasive fecal incontinence device. Developed with Mayo Clinic, it targets a market affecting more than 2% of the global population.
Guardant Health (Shield Across America)
Initiative: Launched a mobile screening tour bringing its Shield colorectal cancer blood test to over 100 rural communities.
The Context: According to recent CDC data, colorectal cancer screening rates in rural areas lag significantly behind urban centers (58.5% in rural counties vs. 66.1% in metropolitan areas), contributing to higher late-stage diagnosis and mortality rates in these regions. Shield is the first and only FDA-approved blood test as a primary CRC screening option.
🌍 Policy & Public Health
TrumpRx Reality Check
Adoption Headwinds: One month after launch, third-party data shows daily searches for the TrumpRx platform have dropped to approximately 11,000 from a high of 569,000 on February 6. The platform currently lists only 44 drugs.
Critique: Critics cite limited drug availability and a lack of real-world "lowest price" transparency as major hurdles. The administration has yet to release official usage statistics.
340B Data Collection Dispute
Lobbying: Hospital groups continue lobbying HRSA to block expanded claims-data collection policies from Eli Lilly and Novo Nordisk. In a March 3 letter, the American Hospital Association urged HRSA to take immediate enforcement action, including civil monetary penalties, against both companies.
FDA Opioid Disposal Initiative
Policy: The agency issued an RFI seeking public comment on new standards for in-home opioid disposal products. Commissioner Makary stated: "Having unused opioids laying around at home can be a significant risk... and a gateway for opioid-naïve family members."
🔒 BioMed Nexus Pro — Institutional Intelligence Brief
In Today's Pro Brief:
🧠 The "Allosteric" Re-Rating: Why Atavistik's $160M raise confirms a structural pivot away from orthosteric inhibitors.
⚖️ J&J Tec-Dara Risk Framing: We model the 83% risk reduction against the looming threat of CAR-T competition in the second-line setting.
🧮 340B Escalation: The administrative cost threshold that could force safety-net hospitals out of the program.
Selective 2026 sponsorship placements are available
Reply directly to discuss a partnership or submit an inquiry here